Genes are the foundation of human life. They are the code that gives every instruction to our bodies about how to move, digest, and think. So understanding those genes can be critical to understanding our own health. It’s no wonder that the clinical sequencing market is expected to have a compound annual growth rate (CAGR) of 14.6% through 2032. With such growth comes profits, and some of the best biotech stocks to buy right now are already building the future of gene testing.
Modern gene testing companies are now serving more than just individual customers. They can also leverage their data to provide a better understanding of diseases and drug targets. This makes them key players in the pharmacology industry, as their data is worth big money to big pharma.
Add to that the continued growth of the gene testing industry as a whole and the future of gene testing looks bright. Here are three of the best gene testing stocks to play the trend.
This post appeared first on InvestorPlace.